Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inmune Bio (INMB) Non Operating Income (2019 - 2025)

Inmune Bio (INMB) has disclosed Non Operating Income for 7 consecutive years, with $210000.0 as the latest value for Q4 2025.

  • Quarterly Non Operating Income fell 15.66% to $210000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.4 million through Dec 2025, up 162.21% year-over-year, with the annual reading at $1.4 million for FY2025, 162.21% up from the prior year.
  • Non Operating Income hit $210000.0 in Q4 2025 for Inmune Bio, down from $961000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $961000.0 in Q3 2025 to a low of -$2.5 million in Q4 2022.
  • Historically, Non Operating Income has averaged $98250.0 across 5 years, with a median of $142500.0 in 2024.
  • Biggest five-year swings in Non Operating Income: soared 12720.0% in 2021 and later plummeted 490.8% in 2022.
  • Year by year, Non Operating Income stood at $641000.0 in 2021, then tumbled by 490.8% to -$2.5 million in 2022, then skyrocketed by 98.84% to -$29000.0 in 2023, then skyrocketed by 958.62% to $249000.0 in 2024, then dropped by 15.66% to $210000.0 in 2025.
  • Business Quant data shows Non Operating Income for INMB at $210000.0 in Q4 2025, $961000.0 in Q3 2025, and $113000.0 in Q2 2025.